表紙
市場調查報告書

阿茲海默症 (AD) :動態市場預測

Alzheimer's Disease: Dynamic Market Forecast to 2026

出版商 GlobalData 商品編碼 742229
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
阿茲海默症 (AD) :動態市場預測 Alzheimer's Disease: Dynamic Market Forecast to 2026
出版日期: 2018年10月09日內容資訊: 英文 52 Pages
簡介

本報告提供阿茲海默症 (AD) 治療藥市場相關調查分析,最新的預測 (法規,上市,臨床實驗活動等) 相關的系統性資訊。

第1章 動態市場預測概要

  • 相關調查
  • 未來的相關調查

第2章 摘要整理

第3章 活動1

  • 主要的更新:單株抗體
  • Biogen:Aducanumab
  • 醫生的見解
  • Roche:Crenezumab
  • 醫生的見解
  • Roche:Gantenerumab
  • 醫生的見解
  • AD的單株抗體的競爭情形
  • 摘要/趨勢
  • 資訊來源

第4章 活動2

  • 主要的更新:BACE抑制劑(血管收縮素轉換酵素抑制劑)和疫苗的組合
  • BASE1以毒性和有效性的問題已停產
  • Eisai:Elenbecestat
  • 醫生的見解
  • Novartis:CNP520
  • 醫生的見解
  • Novartis:CAD106
  • 醫生的見解
  • AD的BACE抑制劑(血管收縮素轉換酵素抑制劑)和疫苗組合的競爭情形
  • 摘要/趨勢
  • 資訊來源

第5章 活動日曆

  • 主要的活動預定

第6章 附錄

目錄
Product Code: GDHC006FS

"Alzheimer's Disease: Dynamic Market Forecast to 2026", research report is designed to help clients stay abreast of the latest news in the Alzheimer's Disease (AD) space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Alzheimer's Disease (AD) is a rapidly evolving field in which new developments are constantly influencing the market landscape.

The Dynamic Market Forecast consists of a slide deck detailing key market-impacting events that have occurred in the Alzheimer's Disease (AD) Space which reflects the projected influence of these events on the future AD market.

The Key Events covered in this Alzheimer's Disease (AD) Dynamic Market Forecast include -

  • Potential first humanized monoclonal antibody for the treatment of AD could enter in the market in 2021
  • Approval and launch of DMT classes will revolutionize the field of AD therapeutics, regardless of their cost and increase competition
  • Three of BACE1 inhibitors have been terminated since September 2017 so elenbecestat is now leading this class due to recently published positive data results
  • Combination of treatment with CNP520 and CAD106 from Novartis could open new option for the treatment of AD
  • Launch of new four pipeline drugs added in the late stage pipeline

Scope

Components of the slide deck include -

  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the AD competitive space through October2018 - October 2021

Other events included in the analysis include -

  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global AD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

  • 1. Dynamic Market Forecast Overview 5
  • 1.1 Related Reports 6
  • 1.2 Upcoming Related Reports 7
  • 2. Executive Summary 8
  • 2.1 Key Updates to AD Market Dynamics 9
  • 2.1 Key Events in Update 10-13
  • 2.2 Clinical Trial Landscape Updates 14-15
  • 2.3 Pipeline Landscape Updates 16
  • 2.4 Market Insight on Key Events 17
  • 3. Event 1: Approval and Launch of DMD Classes Will Revolutionize the Field of AD Therapeutics, Regardless of Their Cost 18
  • 3.1 Key Updates to the Monoclonal Antibodies Market Dynamics 19
  • 3.2 Biogen, Aducanumab 20-21
  • 3.3 What Do Physicians Think? 22
  • 3.4 Roche, Crenezumab 23
  • 3.5 What Do Physicians Think? 24
  • 3.6 Roche, Gantenerumab 25
  • 3.7 What Do Physicians Think? 26
  • 3.8 Competitive Landscape of Monoclonal Antibodies in AD 27
  • 3.9 Summary/Trends 28
  • 3.10 Sources 29
  • 4. Event 2: Recent failures of large late-phase trials have cast doubts over AD drug developers 30
  • 4.1 Key Updates to BACE Inhibitors and Combination with Vaccines Market Dynamics 31
  • 4.2 BACE1 Discontinued in 2018 Based on Toxicity and Efficacy Concerns 32
  • 4.3 Eisai, Elenbecestat 33
  • 4.4 What Do Physicians Think? 34
  • 4.5 Novartis, CNP520 35
  • 4.6 What Do Physicians Think? 36
  • 4.7 Novartis, CAD106 37
  • 4.8 What Do Physicians Think? 38
  • 4.9 Competitive Landscape of BACE Inhibitors and Combination with Vaccines in AD 39
  • 4.10 Summary/Trends 40
  • 4.11 Sources 41
  • 5. Events Calendar 42
  • 5.1 Key Events Expected to Occur in 2018-2021 43

6. Appendix 44

  • 6.1 Methodology 45
  • 6.2 Primary Research 46
  • 6.3 About the Authors 47-49
  • 6.4 About GlobalData 50
  • 6.5 Contact Us 51
  • 6.6 Disclaimer 52